$\label{eq:Kasibante} \mbox{It is made available under a CC-BY 4.0 International license} \ . Kasibante \ CSF \ Protein \ in \ Cryptococcosis$

1	Utility of Cerebrospinal Fluid Protein Levels as a Potential
2	Predictive Biomarker of Disease Severity in HIV-Associated
3	Cryptococcal Meningitis.
4	John Kasibante ¹ , Eesha Irfanullah ² , Abduljewad Wele ² , Elizabeth Okafor ² , Kenneth
5	Ssebambulidde ¹ , Samuel Okurut ¹ , Enock Kagimu ¹ , Jane Gakuru ¹ , Morris K. Rutakingirwa ¹ ,
6	Timothy Mugabi ¹ , Edwin Nuwagira ³ , Samuel Jjunju ¹ , Edward Mpoza ¹ , Lillian Tugume ¹ , Laura
7	Nsangi ¹ , Abdu K Musibire ¹ , Conrad Muzoora ³ , Joshua Rhein ² , David B. Meya ^{1,2} , David R.
8	Boulware ² , Mahsa Abassi ²
9	¹ Infectious Diseases Institute, College of health sciences, Makerere University. P.O. Box 22418,
10	Kampala, Uganda.
11	² Division of Infectious Diseases & International Medicine, Department of Medicine, University
12	of Minnesota, Minneapolis, MN 55455, USA.
13	³ Department of Medicine, Mbarara University of Science and Technology, P.O Box 1410,
14	Mbarara, Uganda.
15	Corresponding author: John Kasibante, email: johnkasi93@gmail.com, jkasibante@idi.co.ug
16	Author contributions: JK conceptualized and developed the initial manuscript draft. EI
17	contributed towards the initial manuscript writing. AW did the statistical analysis. MA, DRB,
18	and DBM mentored JK and EI. All other authors offered comments and edited the manuscript for
19	critical input.
20	
21	Keywords: HIV; cryptococcal meningitis; cerebral spinal fluid; CSF protein; CSF cytokines;

22 predictive biomarker.

It is made available under a CC-BY 4.0 International license . Kasibante CSF Protein in Cryptococcosis

23 Abstract

24 Background.

25 Cerebrospinal fluid (CSF) protein levels exhibit high variability in HIV-associated cryptococcal

- 26 meningitis from being normal to markedly elevated. However, the clinical implications of CSF
- 27 protein levels in cryptococcal meningitis remain unclear.

28 Methods.

29 We analysed data from 890 adults with HIV-associated cryptococcal meningitis randomized into

two clinical trials in Uganda between 2015 and 2021. CSF protein was grouped into $\geq 100 \text{ mg/dL}$

(n=249) and <100 mg/dL (n=641). We described baseline clinical variables and mortality by

32 CSF protein levels.

33 **Results.**

Approximately one-third of individuals had a baseline CSF protein >100 mg/dL. Those with CSF 34 protein $\geq 100 \text{ mg/dL}$ were more likely to present with Glasgow coma scale scores ≤ 15 (P ≤ 0.01), 35 self-reported seizures at baseline (P=0.02), higher CD4 T-cells (p<0.001), and higher CSF white 36 cells (p<0.001). Moreover, those with a baseline CSF protein \geq 100 mg/dL also had a lower 37 baseline CSF fungal burden (p<0.001) and a higher percentage of sterile CSF cultures at day 14 38 (p=0.02). Individuals with CSF protein >100 mg/dL demonstrated a more pronounced immune 39 40 response consisting of upregulation of immune effector molecules pro-inflammatory cytokines, type-1 T-helper cell cytokines, type-3 chemokines, and immune-exhaustion marker (p < 0.05). 18-41 week mortality risk in individuals with a CSF protein <100 mg/dL was 34% higher, (unadjusted 42 43 Hazard Ratio 1.34; 95% CI, 1.05 to 1.70; p=0.02) than those with >100 mg/dL.

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

44 Conclusion.

- 45 In cryptococcal meningitis, individuals with CSF protein $\geq 100 \text{ mg/dL}$ more frequently presented
- 46 with seizures, altered mental status, immune activation, and favourable fungal outcomes.
- 47 Baseline CSF protein levels may serve as a surrogate marker of immune activation and
- 48 prognosis.

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

49 **Background.**

50	Sub-Saharan Africa is home to an estimated 20.1 million of the 38.4 million people living
51	with HIV (PLWH) globally [1]. Since 2010, increased access to HIV testing, antiretroviral
52	therapy (ART), and improved management of opportunistic infections has decreased HIV-
53	associated mortality by 47% [1]. Despite advancements in HIV care and management, HIV-
54	associated opportunistic infections remain a significant burden in sub-Saharan Africa, where
55	54% of cryptococcal meningitis and 63% of all cryptococcal-related mortality occur [2].
56	Cryptococcal meningitis mortality, even in the setting of clinical trials, remains unacceptably
57	high, with 10-week mortality exceeding 25% [3, 4]. Therefore, there is a need to identify and
58	understand the role of predictive biomarkers of cryptococcal meningitis severity to inform
59	targeted interventions and improve outcomes.
60	Cerebrospinal fluid (CSF) proteins are characterized by marked intra-individual and
61	inter-individual variability in healthy individuals with approximately 80% of protein originating
62	from blood and 20% from the central nervous system [5]. Elevated CSF protein therefore
63	indicates either a dysfunction in the blood-CSF or the blood-brain barrier [6]. In healthy
64	individuals, CSF protein levels range between 15 and 60 mg/dL. In cryptococcal meningitis, CSF

65 protein levels are highly variable, ranging from normal levels to as high as >20 times the upper

66 limit of normal [6, 7]. In 1974, Diamond and Bennet found that in cryptococcal meningitis,

67 baseline CSF protein levels were higher in persons who survived compared to those who died

68 [8]. In two recent small retrospective studies, individuals with cryptococcal meningitis and high

69 baseline CSF protein had a better response to antifungal therapy and improvement in clinical

symptoms compared to those with lower baseline CSF protein levels [7, 9]. While existing data

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

offers intriguing insights into the relationship between baseline CSF protein levels and outcomes
in cryptococcal meningitis, it is crucial to acknowledge that the current evidence remains limited
and inconclusive.

Our study aims to enhance our understanding of the role of CSF protein in cryptococcal meningitis and to assesses its potential as a predictive biomarker of severity in HIV-associated cryptococcal meningitis. Additionally, we sought to investigate the relationship between CSF protein levels with established risk factors of severe disease, such as seizures, altered mental status, CD4 T-cell count, CSF fungal burden, CSF opening pressure, and CSF cytokine profile [10-12]. Furthermore, we examined the predictive value of elevated CSF protein as a predictor of mortality.

81 Methods

82 Study Design

We carried out a prospective cohort study of Ugandans adults diagnosed with HIV-83 associated cryptococcal meningitis as a secondary analysis of two randomized clinical trials: (i) 84 the Adjunctive Sertraline for the Treatment of HIV-associated Cryptococcal Meningitis 85 (ASTRO-cm) trial enrolled from March 9, 2015, to May 29, 2017; and (ii) the AMBIsome 86 Therapy Induction Optimisation (AMBITION-cm) trial enrolled from January 2018 through 87 88 February 2021 [3, 4]. A detailed description of the study design for each clinical trial is published elsewhere [4, 13]. In brief, the ASTRO-cm trial investigated the impact of adjunctive 89 sertraline on cryptococcal meningitis treatment outcomes. The AMBITION-cm trial investigated 90 91 the efficacy of single high-dose liposomal amphotericin B on fluconazole and flucytosine

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

92	backbone in cryptococcal meningitis. Participants were recruited and enrolled at Mulago
93	National Specialist Hospital, Kiruddu National Referral Hospital, and Mbarara Regional Referral
94	Hospital in Uganda. All participants diagnosed with a first episode of HIV-associated
95	cryptococcal meningitis by a positive finger stick and CSF cryptococcal antigen (CrAg) were
96	included in this analysis [14, 15]. All study participants had a diagnostic LP performed at
97	baseline. CSF samples were collected and sent to the laboratory and analysed for CSF cell
98	counts, quantitative fungal cultures, and protein concentration.
99	Ethical approvals for both clinical trials were granted from the Mulago Hospital Research

and Ethics Committee, the Uganda National Council of Science & Technology, and the
 University of Minnesota Institutional Review Board. All participants or their surrogate provided
 their written consent for study participation.

103 Cytokine quantification

We assessed CSF cytokine and chemokine concentrations at baseline among a subset of 104 the ASTRO-CM study participants. CSF samples were centrifuged at 400g for 4 minutes at 4°C, 105 supernatant was collected and stored at -80°C. Frozen samples were transported to the University 106 of Minnesota and cytokines/chemokines were measured using the Human Luminex Discovery 107 Assay (R&D systems, Minneapolis, MN, USA). The 43 cytokine and chemokine assay included 108 mediators of inflammatory response: interleukin (IL) -1a, IL-1b, IL-6, platelet derived growth 109 factor (PDGF)-AA, PDGF-AB, and vascular endothelial growth factor (VEGF); type-1 T helper 110 cell (Th1) associated cytokines: macrophage inflammatory protein (MIP)1a/CCL3, 111 MIP1b/CCL4, RANTES/CCL5, tumor necrosis factor (TNF)- α, IL-12, IL-15, interferon (IFN)-112 113 γ , interferon-inducible protein (IP)-10/CXCL10, granulocyte-macrophage colony stimulating

It is made available under a CC-BY 4.0 International license . Kasibante CSF Protein in Cryptococcosis

114 factor (GM-CSF), and granzyme B; **Th2 cytokines**: IL-4, IL-5, IL-13, IL-25, IL-33, and eotaxin;

115 **Th3 cytokines**: MIP3a/CCL20, growth-related oncogene (GRO)- α /CXCL1, GRO- β /CXCL2,

116 CXCL8/IL-8, IL-17A, and granulocyte colony stimulating factor (G-CSF); modulators of

immune response: IL-10, IL-1 receptor antagonist (IL-1ra), Endothelial growth factor (EGF),

and transforming growth factor (TGF)- α ; immune exhaustion: programmed death ligand-1 (PD-

119 L1), **Type-1 interferon-** α and interferon- β , and **non-classified chemokines**: MIP3b/CCL19, IL-

120 3, CD40 ligand/TNFSF5, fractalkine/CX3CL1, Flt3 ligand,

121 Statistical methods

We initially divided patients into tertiles: low CSF protein (0 to < 45 mg/dL), middle 122 123 CSF protein (>45 mg/dL to <100 mg/dL), and high CSF protein (>100 mg/dL). We found no significant difference between the low and middle tertile groups in terms of survival, and 124 therefore we combined them into an aggregate CSF protein group of <100 mg/dL. We 125 126 summarized baseline demographic variables and laboratory parameters by CSF protein <100mg/dL vs. CSF protein $\geq 100 mg/dL$. We also evaluated the impact of ART status at enrollment 127 on CSF protein levels and its contribution to clinical presentation and outcomes given the role 128 that ART plays in unmasking immune reconstitution inflammatory syndrome (IRIS). Data are 129 presented as median with interguartile range (IOR) or proportions with statistical testing via 130 Kruskal-Wallis's test for medians and Fisher's exact tests for proportions. P values <0.05 were 131 considered statistically significant. We adjusted cytokine P-values with the Benjamini-Hochberg 132 procedure to control the false discovery rate [16]. We compared survival by Kaplan-Meier 133 curves and Cox proportion hazard regression analysis using both the adjusted and unadjusted 134 models. The adjusted survival model included differentially distributed co-variates between 135 groups, including CSF opening pressure >250 mmH₂O, CSF white cell count, seizures, and CSF 136

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

- 137 cryptococcal quantitative colony forming units (CFUs). Quantitative CFUs were log_{10}
- transformed for normalization. We conducted all analyses with SAS version 9.4 (SAS Institute,

139 Cary, NC).

140 **Results**

141 **Demographics**

We included 890 adults with HIV-associated cryptococcal meningitis in our analysis.

- 143 72% (641/890) had CSF protein levels <100 mg/dL at baseline. We found no statistically
- significant differences in age, gender, and weight at baseline between CSF protein groups "Table
- 145 1". While there was no difference between the percentage of persons who were on ART (p=0.82)
- 146 or the duration of time on ART (p=0.05) at baseline, we found a statistically significant higher
- 147 CD4 T-cell count in persons with CSF protein $\geq 100 \text{ mg/dL}$ (median CD4 = 28, IQR 10 to 65
- 148 cells/ μ L) as compared to persons with CSF protein <100 mg/dL (median CD4 = 15, IQR 6 to 41
- 149 cells/ μ L; p<0.001). Individuals with CSF protein \geq 100 mg/dL presented with more self-reported
- seizures (p=0.02) and a Glasgow Coma Scale score <15 (p<0.01) compared to those with CSF
- 151 protein <100 mg/dL.

It is made available under a CC-BY 4.0 International license .

Kasibante CSF Protein in Cryptococcosis

153 Table 1. Clinical Parameters and Treatment Outcomes by Baseline CSF

154

Protein Levels

155

	N	CSF Protein <100 mg/dL (N = 641)	N	CSF Protein ≥100mg/dL (N = 249)	P-value ¹
Age (years)	641	35 [30, 40]	249	35 [30, 42]	0.46
Female	641	264 (41)	249	87 (35)	0.09
Weight (kg)	561	50 [46, 60]	224	53 [47, 60]	0.26
Antiretroviral Therapy (ART) Status					
Currently on ART	640	307 (48)	249	117 (47)	0.82
Months on ART	306	4 [1, 32]	115	3 [1, 13]	0.05
≤14 Days	306	51 (17)	115	26 (23)	0.10
15-30 Days		37 (12)		11 (10)	
31-90 Days		45 (15)		25 (22)	
>90 Days		173 (57)		53 (46)	
Clinical					
Seizures	641	92 (14)	249	52 (21)	0.02
Glasgow Coma Scale <15	640	231 (36)	249	114 (46)	<0.01
CD4 <50 cells/mm ³ categorical	614	485 (79)	240	158 (66)	< 0.001
CD4 cells/mm ³	614	15 [6, 41]	240	28 [10, 65]	< 0.001
CSF Opening Pressure mmH ₂ O					
Baseline	590	259 [170, 390]	234	255 [170, 350]	0.22
Day 3	149	300 [196, 420]	54	290 [210, 400]	0.77
Day 7	292	180 [110, 280]	119	180 [100, 268]	0.34
Day 14	223	210 [130, 295]	98	157[100, 240]	<0.01
Quantitative CSF Culture, log 10 CFU/mL					
Baseline	622	4.68 [3.2, 5.5]	247	4.09 [2.3, 5.3]	<0.001
Day 3	156	4.45 [3.1, 5.2]	60	3.48 [2.2, 4.9]	0.04
Day 7	313	1.91 [0.0, 3.6]	131	0.00 [0.0, 2.8]	<0.01
Day 14	245	0.00 [0.0, 1.7]	102	0.00 [0.0, 1.2]	0.38
CSF White Cell cells/mm ³					
CSF <5 white cells/mm ³	636	460 (72)	246	77 (31)	<0.001
Baseline	636	<5 [<5, 10]	246	53 [<5, 150]	<0.001
Day 3	159	<5 [<5, 30]	60	28 [<5, 138]	<0.001
Day 7	312	<5 [<5, 45]	130	35 [<5, 95]	<0.001
Day 14	248	<5 [<5, 25]	103	25 [<5, 65]	<0.001
CSF Sterility status					
Baseline Sterile Culture	622	47 (8)	247	28 (11)	0.08
Day 14 Sterile Culture	429	191 (45)	149	83 (56)	0.02
Early Fungicidal Activity, log ₁₀ CFU/mL/d	474	0.333 (0.186, 0.480)	191	0.326 (0.208, 0.482)	0.43

Data are represented as Median [IQR] or N (%)

¹Kruskal-Wallis test for medians; Fisher Exact tests for proportions

Day 3, 7, and 14 values are collected within -/+1 day within the visit window

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

157 **CSF characteristics**

158	Baseline CSF white cells were significantly higher in individuals with CSF protein ≥ 100
159	mg/dL (median 53, IQR \leq 5 to 150 white cells/mm ³ CSF) compared to those with CSF protein
160	<100 mg/dL (median <5, IQR <5 to 10 white cells/mm ³ CSF; p <0.001). CSF white cell counts
161	remained significantly higher through days 3, 7, and 14 among individuals with CSF protein
162	\geq 100 mg/dL as compared to CSF protein <100 mg/dL (p<.001). Baseline CSF quantitative
163	cryptococcal cultures were significantly lower in persons with CSF protein $\geq 100 \text{ mg/dL}$ (median
164	12 300, IQR 200 to 200 000 CFU/mL) compared to persons with CSF protein $<100 \text{ mg/dL}$
165	(median 48 000, IQR 1585 to 316 000 CFU/mL; p<0.001). At day 14, the proportion of persons
166	with a sterile CSF culture was higher in those with CSF protein $\geq 100 \text{ mg/dL}$ compared to those
167	with CSF protein $\leq 100 \text{ mg/dL}$ (CSF protein $\geq 100 \text{ mg/dL} 56\%$ (83/149) vs. CSF protein ≤ 100
168	mg/dL 45% (191/429); p=0.02). We found no differences in baseline CSF opening pressure
169	between individuals with CSF protein $\geq 100 \text{ mg/dL}$ compared to CSF protein $< 100 \text{ mg/dL}$
170	(p=0.22).
171	CSF cytokine assays revealed that individuals with CSF protein $\geq 100 \text{ mg/dL}$ had
172	significantly higher levels of pro-inflammatory cytokines, interleukin(IL)-1β, IL-6, PDGF-AA
173	and VEGF; type-1 T helper cell (Th1) response cytokines IL-12, IL-15, interferon- γ , TNF- α , and
174	GM-CSF; effector molecules granzyme B and TRAIL; type-2 T helper cell (Th2) response
175	cytokine IL-5 and Eotaxin; type 3/ Th17 related cytokines IL-17, G-CSF, CXCL1, CXCL2,
176	CXCL8, and CCL20; and immune exhaustion marker PD-L1; as compared to those with CSF

177 protein <100 mg/dL "Table 2".

178

It is made available under a CC-BY 4.0 International license .

Kasibante CSF Protein in Cryptococcosis

179 Table 2: Baseline CSF Cytokines and Chemokines by Baseline CSF Protein

180

Levels

CSF Biomarker, pg/mL (log2)	N	CSF Protein < 100 mg/dL Median (IQR)	N	CSF Protein ≥ 100 mg/dL Median (IQR)	P-value*	P-value**
Mediate inflammatory respons	es					
IL-1a	229	3.8 [1.4, 6.8]	84	5.4 [2.8, 7.6]	0.0701	0.1018
IL-6	229	116 [36.7, 733]	84	380 [119, 2343]	0.0004	0.0045
IL-1b	229	2.4 [1.0, 3.8]	84	3.3 [1.9, 5.7]	0.0011	0.0062
PDGF-AA	228	81.8 [48.8, 117]	84	99.8 [57.6, 174]	0.0069	0.0141
PDGF-AB	229	2.6 [0.4, 4.3]	84	3.6 [0.8, 5.2]	0.1109	0.1426
VEGF	229	44.9 [28.7, 75.5]	84	59.8 [31.9, 100.0]	0.0166	0.0311
FGF Basic	229	1.5 [0.3, 1.5]	84	1.5 [0.3, 5.0]	0.0892	0.1181
Type 1 T helper cell (Th ₁) imm	une res	sponse, ideal for effective in	tracellul	ar killing of Cryptococcus		
IL-12	229	5.2 [0.8, 10.0]	84	8.0 [3.6, 13.2]	0.0058	0.0131
IL-15	229	3.5 [2.4, 5.1]	84	3.4 [2.5, 5.0]	0.8414	0.8414
Interferon-y	229	4.2 [0.4, 9.5]	84	8.3 [1.5, 16.9]	0.0018	0.0062
TNF-α	229	40.8 [16.1, 90.9]	84	64.3 [29.3, 142.4]	0.0046	0.0115
GM-CSF	229	33.7 [22.5, 54.7]	84	46.4 [26.8, 81.5]	0.0033	0.0099
Granzyme B	229	12.3 [3.5, 21.8]	84	21.1 [11.5, 82.1]	0.0000	0.0000
TRAIL	229	7.0 [2.5, 12.3]	84	10.9 [4.8, 14.9]	0.0017	0.0064
MCP1/CCL2	229	831 [497, 2207]	84	998 [578, 2265]	0.4399	0.4828
MIP1a/CCL3	229	36.6 [20.4, 66.5]	84	50.6 [29.7, 78.2]	0.0418	0.0672
MIP1b/CCL4	229	166 [109, 247]	84	190 [121, 305]	0.0599	0.0899
Rantes/CCL5	137	40.8 [4.1, 99.1]	58	73.3 [4.1, 143.7]	0.3302	0.3715
IP10/CXCL10	229	2336 [1027, 2900]	84	2568 [1400, 3139]	0.1525	0.1855
Type 2 T helper cell (Th ₂) imm	une res	sponse, not protective again	st Crypta	ococcus		
IL-4	229	1.6 [0.7, 2.6]	84	1.5 [0.6, 2.3]	0.6020	0.6300
IL-5	229	0.9 [<0.1, 3.2]	84	2.8 [0.2, 4.7]	0.0001	0.0023
IL-13	229	22.3 [13.7, 34.5]	84	29.3 [14.5, 38.9]	0.1326	0.1658
IL-33	229	7.6 [2.0, 13.1]	84	10.1 [3.6, 17.1]	0.0762	0.1039
IL-25	229	17.0 [4.9, 34.9]	84	17.7 [7.4, 31.9]	0.7725	0.7901
Eotaxin	229	14.5 [9.2, 19.9]	84	18.2 [11.1, 23.1]	0.0084	0.0164
Type 3 immune response, invol	lves neu	utrophils mediated inflamm	ation			
IL-17A	229	2.0 [0.2, 4.4]	84	3.9 [0.9, 7.7]	0.0006	0.0045
GCSF	229	30.9 [13.2, 68.3]	84	45.4 [18.6, 108.2]	0.0222	0.0400
GROa/CXCL1	229	144.5 [57.5, 435]	84	362 [95.1, 667]	0.0005	0.0045
GROb/CXCL2	229	15.2 [6.6, 25.9]	84	19.8 [8.5, 43.0]	0.0054	0.0128
IL8/CXCL8	228	289 [119, 814]	84	584 [269, 1777]	0.0009	0.0058
MIP3a/CCL20	229	4.5 [1.3, 8.4]	84	6.9 [3.2, 10.5]	0.0017	0.0070
Modulate/dampen all 3 types o	f immu	ine responses				
IL-1ra	228	4199 [1271, >10000]	84	7237 [3590, >10000]	0.0012	0.0060
IL-10	229	229 [155, 332]	84	263 [176, 393]	0.0524	0.0813

It is made available under a CC-BY 4.0 International license .

Kasibante CSF Protein in Cryptococcosis

IL-2	229	4.7 [2.3, 8.3]	84	7.1 [3.3, 10.8]	0.0035	0.0098
TGF-α	229	9.3 [5.4, 15.1]	84	11.5 [5.6, 20.4]	0.0384	0.0640
EGF	229	1.3 [0.6, 6.0]	84	3.2 [0.6, 7.7]	0.1937	0.2294
Immune exhaustion (with	HIV and cry	ptococcal chronic infecti	ons)			
PDL-1	229	97.9 [51.0, 166.9]	84	161.5 [67.8, 265.5]	0.0004	0.0060
With G-CSF, GM-CSF, stimulate production of immune cells in the bone marrow						
IL-3	229	4.6 [0.7, 15.0]	84	7.1 [0.7, 17.4]	0.2022	0.2333
Other cytokines						
MIP3b/CCL19	229	81.6 [34.4, 175.5]	84	146.4 [50.3, 273.3]	0.0037	0.0098
TNFSF5/CD40-L	229	384 [65.2, 636]	84	529 [251, 835]	0.0025	0.0080
Fractalkine/CX3CL1	229	292.0 [174.3, 444.5]	84	383.1 [240.6, 596.2]	0.0015	0.0068
Flt-3Ligand	229	97.3 [64.0, 141.1]	84	122.5 [81.4, 171.0]	0.0062	0.0133
Type 1 Interferons, gener	ally for anti-v	iral responses and down	regulates	Th ₁ immune responses.		
Interferon-α	229	4.3 [1.9, 9.4]	84	5.5 [3.0, 9.7]	0.0748	0.1052
Interferon-β	229	0.3 [0.1, 2.0]	84	1.1 [0.2, 2.6]	0.0277	0.0479

*P-values from Wilcoxon test.

**Adjusted P value by Benjamini Hochberg procedure to control false discovery rate.

Abbreviations: MIP, Macrophage inflammatory protein; TNF, tumor necrosis factor; GRO, growth-related oncogene; IL-interleukin; IL-1ra, interleukin-1 receptor antagonist; IFN, Interferon; IP-10, interferon-inducible protein; G-CSF, granulocyte colony stimulating factor; GM-CSF, granulocyte-macrophage colony stimulating factor; PDL-1, programmed death ligand-1; EGF, Endothelial growth factor; TGF, transforming growth factor; PDGF, platelet derived growth factor; VEGF, vascular endothelial growth factor.

181

182 Effect of ART on CSF Protein Levels

183 ART status at study enrolment influenced clinical parameters in both CSF protein

184 categories "Table 3". Individuals on ART and with a baseline CSF protein $\geq 100 \text{ mg/dL}$ were

more likely to present with a Glasgow coma scale score <15 as compared to persons on ART and

- with a baseline CSF protein <100 mg/dL (98/307 vs. 50/117, p<0.04). There was no difference in
- 187 Glasgow coma scale score <15 between CSF protein groups in individuals who were not

receiving ART on admission (p=0.10). Persons with a baseline CSF protein $\geq 100 \text{ mg/dL}$ had a

higher CD4 T-cell count, higher CSF white cell count at baseline and through day 14, and a

- 190 lower baseline CSF fungal burden compared to persons with CSF protein <100 mg/dL,
- irrespective of baseline ART status. Individuals on ART with a CSF protein $\geq 100 \text{ mg/dL}$ had a
- 192 higher percentage of sterile cultures at day 14 compared to individuals on ART and with a CSF

It is made available under a CC-BY 4.0 International license . Kasibante CSF Protein in Cryptococcosis

protein <100 mg/dL (p<0.01). There was no difference in the percentage of day 14 sterile

194 cultures between CSF protein groups in those who were not on ART at baseline (p=0.78).

Table 3: Clinical Presentation and Outcomes by Baseline CSF Protein Levels

196

and ART Status

	Receiving Antiretroviral therapy at Baseline				NOT Receivir	ng Anti	retroviral therapy	r		
		CSF protein		CSF protein	P_		CSF protein		CSF protein	P_
		<100 mg/dL		≥100mg/dL	r - value ¹		<100 mg/dL		≥ 100mg/dL	1 - value ¹
	Ν	(N=307)	Ν	(N=117)	value	Ν	(N=333)	Ν	(N=132)	value
Demographics										
Age, years	307	35 [30, 40]	117	35 [30, 42]	0.35	333	35 [30, 41]	132	35 [30, 42]	0.90
Female	307	134 (44%)	117	41 (35%)	0.12	333	130 (39 %)	132	46 (35%)	0.46
Weight, kg	278	50 [46, 58]	107	52 [46, 59]	0.52	283	51 [47, 60]	117	54 [48, 60]	0.40
Clinical										
Seizures	307	37 (12%)	117	21 (18%)	0.12	333	55 (17%)	132	31 (24%)	0.09
Glasgow Coma scale<15	307	98 (32%)	117	50 (43%)	0.04	332	132 (40%)	132	64 (49%)	0.10
CD4<50 cells/mm ³	294	217 (74%)	112	59 (53%)	< 0.01	319	267 (84%)	128	99 (77%)	0.13
CD4, cells/mm ³	294	20 [8, 52]	112	42 [16, 88]	< 0.01	319	13 [6, 33]	128	19 [8, 45]	<0.01
Opening Pressure, mmH ₂ O										
Baseline	282	245 [170, 370]	108	260 [180, 350]	0.99	307	270 [170, 400]	126	250 [160,340]	0.10
Day 3	67	286 [190, 395]	27	268 [180, 400]	0.94	81	320 [200, 450]	27	304 [210,401]	0.69
Day 7	136	180 [120, 262]	57	180 [110, 248]	0.52	156	190 [106, 293]	62	185 [90, 280]	0.46
Day 14	106	200 [120, 290]	39	150 [100, 240]	0.07	117	230 [140, 300]	59	160 [90, 240]	0.01
CSF Culture, log 10 CFU/mL										
Baseline	299	4 [2.5, 5.2]	116	3 [1.6, 4.6]	<0.01	322	5 [3.9, 5.6]	131	5 [3.3, 5.5]	0.04
Day 3	73	4 [1.6, 5.0]	31	3 [1.5, 4.7]	0.36	82	5 [4.0, 5.3]	29	4 [2.4, 5.0]	0.06
Day 7	146	2 [0.0, 3.3]	64	0 [0.0, 2.1]	<0.01	167	2 [0.0, 3.7]	67	1 [0.0, 3.2]	0.18
Day 14	116	0 [0.0, 1.6]	40	0 [0.0, 1.0]	0.51	129	0 [0.0, 2.1]	62	0 [0.0, 1.4]	0.47
CSF White cells/mm ³										
CSF <5 white cells/mm ³	304	214 (70%)	115	29 (25%)	<0.01	331	246 (74%)	131	48 (37%)	<0.01
Baseline	304	<5 [<5, 18]	115	70 [<5, 205]	<0.01	331	<5 [<5, 5]	131	40 [<5, 140]	<0.01
Day 3	73	<5 [<5, 35]	31	30 [<5, 120]	<0.01	85	<5 [<5, 25]	29	25 [<5, 240]	<0.01
Day 7	146	<5 [<5, 35]	63	40 [<5, 85]	<0.01	166	<5 [<5, 50]	67	30 [<5, 115]	<0.01
Day 14	117	<5 [<5, 30]	41	<5 [<5, 65]	0.04	131	<5 [<5, <5]	62	28 [<5, 65]	<0.01
CSF sterility										
Baseline	299	34 (11%)	116	19 (16%)	0.19	322	13 (4%)	131	9 (7%)	0.23
Day 14	212	101 (48%)	78	52 (67%)	<0.01	216	89 (41%)	71	31 (44%)	0.78
Mortality										
2 Weeks	307	74 (24%)	117	22 (19%)	0.30	333	84 (25%)	132	27 (21%)	0.33
18 Weeks	307	127 (41%)	117	42 (36%)	0.32	333	150 (45%)	132	44 (33%)	0.02

Data are represented as Median [IQR] or N (%)

¹Kruskal-Wallis test for medians; Fisher Exact tests for proportions

Day 3, 7, and 14 values are collected within -/+1 day within the visit window

198 Outcomes

199 CSF protein levels influenced survival outcomes. Through 18 weeks, those with a CSF

200 protein <100 mg/dL were at a 34% higher risk of death compared to individuals with CSF

201 protein ≥100 mg/dl (Hazard Ratio=1.34; 95% CI 1.05 to 1.70; p=0.02) "Table 4, Fig 1a".

¹⁹⁷

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

Adjustment for baseline CSF fungal burden, Glasgow coma scale score <15, CSF white count,

- 203 CSF opening pressure, and baseline self-reported seizures, attenuated the 18-week mortality risk
- between CSF protein groups (adjusted Hazard Ratio = 1.24; 95%CI, 0.94 to 1.64; p=0.13).
- 205 Mortality rates through 18-weeks differed by ART status. Mortality was highest among
- individuals who were not on ART and had a baseline CSF protein <100 mg/dL (150/333)
- 207 compared to CSF protein \geq 100 mg/dL (44/132) (p=0.02), while mortality through 18-weeks was

similar in individuals on ART and CSF protein (44/132) (p=0.02) "Fig 1b".

209 Table 4. Mortality by Baseline CSF Protein Levels

		CSF Protein	CSF Protein	D voluo	
		<100 mg/dL	≥100 mg/dL	i -value	
Deaths within 2 Weeks	No. Patients	641	249		
	No. (%) with Event	159 (25)	49 (20)		
	Hazard Ratio (95% CI)				
	Unadjusted	1.30 (0.95 - 1.80)	REF	0.10	
	Adjusted ¹	1.15 (0.80 - 1.67)	REF	0.45	
Deaths within 18 Weeks	No. Patients	641	249		
	No. (%) with Event	278 (43)	86 (35)		
	Hazard Ratio (95% CI)				
	Unadjusted	1.34 (1.05 - 1.70)	REF	0.02	
	Adjusted ¹	1.24 (0.94 - 1.64)	REF	0.13	

 1 Adjusted for Baseline CSF quantitative culture log_{10} CFU/mL, Glasgow Coma Scale, CSF White Cell, Baseline Opening Pressure, and Seizures

210

Figure 1. Kaplan- Meier curves of 18-week survival by baseline CSF protein

levels alone (1a) and by baseline CSF protein levels and ART status (1b).

213

214 **Discussion**

215 We demonstrate that in cryptococcal meningitis, persons presenting with CSF protein

 $\geq 100 \text{ mg/dL}$ had better overall 18-week survival and more frequently presented with altered

217 mental status, seizures, higher CSF white cell count, and a lower CSF quantitative cryptococcal

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

culture. When stratified by ART status, only individuals receiving ART and a CSF protein ≥ 100 218 219 mg/dL presented more frequently with altered mental status. Furthermore, CSF protein >100 mg/dL was associated with higher levels of CSF pro-inflammatory, type-1, and type-3 cytokine 220 response. We found a 34% increased hazard of 18-week mortality among individuals with a 221 baseline CSF protein <100 mg/dL as compared to those with CSF protein >100 mg/dL. After 222 adjusting for CSF fungal burden, Glasgow coma scale score <15, CSF white cell count, CSF 223 opening pressure, and baseline self-reported seizures, the 18-week mortality difference was only 224 partially attenuated with a remaining 24% increased hazard in mortality that was not statistically 225 226 different but unexplained by traditional risk factors. Taken together, these findings suggest that CSF protein is a possible predictive biomarker of cryptococcal meningitis severity that is easily 227 accessible at baseline unlike quantitative CSF fungal cultures, which take 7 or more days and are 228 229 not performed in most routine clinical care settings.

In cryptococcal meningitis, high baseline CSF fungal burden and slow rate of fungal 230 clearance are independent predictors of increased mortality at 2 and 10 weeks [10, 12, 17]. 231 Baseline CSF fungal burden and rate of fungal clearance are influenced by the degree of cell-232 mediated immunity and host inflammatory response in cryptococcal meningitis [18]. Higher 233 234 CD4 T-cell count, CSF white cell count, and CSF pro-inflammatory cytokines, IL-6, interferon- γ , and TNF- α , are associated with a lower CSF fungal burden, a more rapid rate of fungal 235 clearance, and improved survival [11, 18-20]. We found that individuals with a baseline CSF 236 237 protein $\geq 100 \text{ mg/dL}$ presented with a higher CD4 T-cell count and a higher CSF white blood cell count, suggesting the presence of a robust inflammatory response compared to those with a CSF 238 protein <100 mg/dL, even in the absence of ART. 239

It is made available under a CC-BY 4.0 International license . Kasibante CSF Protein in Cryptococcosis

In murine models of Cryptococcus neoformans infection, recruitment of CD4⁺ and CD8⁺ 240 leukocytes coincided with CSF cytokine production, white cell recruitment and fungal clearance 241 [21]. In the current study, individuals with CSF protein >100 mg/dL exhibited a predominantly 242 pro-inflammatory cytokine response skewed towards type-1 and type-3 T helper cell immune 243 responses. These individuals also exhibited higher levels of some type-2 T helper cell and 244 245 immune-modulatory cytokines; but this was to a lesser extent (<50% of cytokines in these categories were statistically significant). The elevated levels of chemokines, CXCL1, CXCL2, 246 CXCL8, and CCL20, responsible for T cells, B cells, dendritic cells, monocytes, and neutrophils 247 248 recruitment, would explain the higher CSF white cell count observed in those with CSF protein \geq 100 mg/dL [11, 18, 20, 22-25]. Moreover, we noted increased expression of the immuno-249 250 regulatory cytokines, IL-1ra and IL-2, and the immune exhaustion protein PD-L1, which 251 suppress activated T-cells, in those with CSF protein $\geq 100 \text{ mg/dL}$, suggesting a possible attenuation of damaging inflammatory effects of activated T-cells [21, 26-28]. The combination 252 of this cytokine and cellular response, along with the anti-cryptococcal activity of Granzyme B, 253 likely explains the lower baseline CSF fungal burden and a higher percentage of sterile CSF 254 cultures at day 14 among individuals with CSF protein $\geq 100 \text{ mg/dL}$ [18, 29, 30]. 255

Cell-mediated immunity plays a crucial role in protecting against the development of
cryptococcal disease and promoting fungal clearance [21, 31]. Deficiency in CD4 T-cells
increases the susceptibility to cryptococcal meningitis and is associated with cryptococcal-related
mortality [31, 32]. While most cases of HIV-associated cryptococcal meningitis occur when CD4
T-cell counts drop below 100 cells/µL, approximately 10-20% of cryptococcosis occurs at higher
CD4 T-cell counts [32]. Higher CD4 T-cell counts are more frequently associated with altered
mental status and lower CSF burden of *Cryptococcus* [32]. Despite low median CD4 T-cell

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

263	counts in both CSF protein groups, corresponding to advanced HIV disease, individuals with
264	CSF protein $\geq 100 \text{ mg/dL}$ had a statistically significant higher baseline CD4 T-cell count,
265	suggesting the possibility of an enhanced T-cell mediated immune response to Cryptococcus.
266	The enhanced T-cell mediated immune response and presence of increased levels of CSF
267	cytokines when CSF protein $\geq 100 \text{ mg/dL}$ may explain the resulting lower baseline CSF fungal
268	burden, higher percentage of sterile cultures at 2 weeks, as well as the occurrence of altered
269	mental status and seizures at baseline. Ultimately, additional research is needed to thoroughly
270	investigate the functionality of CD4 T-cells in the context CSF protein in cryptococcal
271	meningitis.

Despite the higher CSF white cell count, lower CSF fungal burden, and higher levels of 272 CSF cytokines in individuals with a CSF protein $\geq 100 \text{ mg/dL}$, the survival advantage was 273 negated after adjusting for established risk factors of cryptococcal mortality. Notably, altered 274 mental status was observed in 46% of individuals with a CSF protein \geq 100 mg/dL at baseline. 275 We have previously demonstrated that altered mental status in cryptococcosis is most likely 276 associated with a dysfunctional host immune response [33]. Here, we demonstrate a robust 277 inflammatory response in individuals with CSF protein >100 mg/dL, characterized by a 278 279 predominantly pro-inflammatory cytokine response skewed toward type-1 T helper cell and type-3 immune responses. Taken together, our findings suggest that individuals with 280 cryptococcal meningitis presenting with altered mental status and a baseline CSF protein ≥ 100 281 282 mg/dL may be exhibiting a robust inflammatory response leading to neurologic deterioration and death [21]. This is consistent with the damage-response framework proposed by Pirofski and 283 Casadevall, a strong host-mediated inflammatory response during cryptococcal infection can 284 inflict host damage, neurological impairment, and death [34]. 285

It is made available under a CC-BY 4.0 International license . Kasibante CSF Protein in Cryptococcosis

Our study has several limitations. Our study population consisted of only people living 286 with HIV and hence may not be generalizable to cases of non-HIV associated cryptococcal 287 meningitis. We measured CSF cytokine levels only at baseline, and inflammation changes over 288 time [35]. We recognize that cytokine levels can fluctuate over time, and we may not have 289 captured the complete dynamics of the immune response in cryptococcal meningitis. We did not 290 291 assess serum protein levels, which would have allowed for a better evaluation of the CSF to serum protein ratio. The ratio provides information about the permeability and integrity of the 292 blood-brain barrier during meningeal inflammation, which would affect CSF protein level [36]. 293 294 Lastly, our study combined data from two separate clinical trials which may affect the internal validity of the study. 295

In conclusion, we have demonstrated that baseline CSF protein levels can serve as a 296 297 surrogate marker of immune activation in cryptococcal meningitis and provide valuable information on disease severity. Individuals with CSF protein $\geq 100 \text{ mg/dL}$ exhibited a more 298 robust immune response against cryptococcal disease, as indicated by a lower CSF fungal burden 299 at baseline and a higher percentage of sterile CSF cultures at day 14. On the other hand, 300 individuals with a CSF protein <100 mg/dL, particularly those not on ART, demonstrated a 301 deficient or absent cell-mediated immune response, manifested by a higher CSF fungal burden at 302 baseline, lower CSF white blood cell count, fewer sterile cultures at day 14, and higher 18-week 303 morality. Further studies are warranted to investigate the potential of CSF protein levels as a 304 305 rapid predictive tool for identifying individuals who would benefit from targeted immunomodulatory therapy to either dampen an exaggerated immune response or augment a 306 307 deficient immune response.

308

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

309 Acknowledgements.

- 310 ASTRO-cm and AMBITION-cm study Team Members. Reuben Kiggundu, Andrew
- 311 Akampurira, Paul Kirumira, Jane Francis Ndyetukira, Cynthia Ahimbisibwe, Florence Kugonza,
- 312 Carolyne Namuju, Alisat Sadiq, Tadeo Kiiza Kandole, Tony Luggya, Julian Kaboggoza, Eva
- Laker, Alice Namudde, Sarah Lofgren, Richard Kwizera, Irene Rwomushana, Mike Ssemusu,
- Joan Rukundo, James Mwesigye, Kirsten Nielsen, Anna Stadelman, Ananta S. Bangdiwala,
- 315 David Lawrence and Nabila Youssouf.
- 316

317 **Financial support**.

- 318 This work was supported by the National Institute of Neurologic Diseases and Stroke
- 319 (R01NS086312, K23NS122601); the Fogarty International Center (K01TW010268,
- R25TW009345); the National Institute of Allergy and Infectious Diseases (T32AI055433);
- 321 United Kingdom Medical Research Council / DfID / Wellcome Trust Global Clinical Trials
- 322 (grant numbers M007413/1, MR/P006922/1); Grand Challenges Canada (S4-0296-01); and the
- European and Developing Countries Clinical Trials Partnership (EDCTP) (TRIA2015-1092)
- with assistance from the Swedish International Development Cooperation Agency (SIDA), the
- 325 U.K. Department of Health and Social Care, the U.K. Foreign Commonwealth and Development
- 326 Office, and the U.K. Medical Research Council.

327

Potential conflicts of interest.

329 All authors: no reported conflicts of interest.

It is made available under a CC-BY 4.0 International license . *Kasibante CSF Protein in Cryptococcosis*

References.

- 1. UNAIDS. Global HIV & AIDS statistics Fact sheet.
- 332 <u>https://www.unaidsorg/en/resources/fact-sheet</u> 2021.
- Rajasingham R, Govender NP, Jordan A, Loyse A, Shroufi A, Denning DW, et al. The
 global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling
 analysis. *Lancet Infect Dis* 2022; 22: 1748-55.
- Jarvis JN, Lawrence DS, Meya DB, Kagimu E, Kasibante J, Mpoza E, et al. Single-Dose
 Liposomal Amphotericin B Treatment for Cryptococcal Meningitis. *N Engl J Med* 2022;
 386: 1109-20.
- 339 4. Rhein J, Huppler Hullsiek K, Tugume L, Nuwagira E, Mpoza E, Evans EE, et al.
 340 Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo341 controlled, double-blind phase 3 trial. *Lancet Infect Dis* 2019; 19: 843-51.
- Schilde LM, Kösters S, Steinbach S, Schork K, Eisenacher M, Galozzi S, et al. Protein
 variability in cerebrospinal fluid and its possible implications for neurological protein
 biomarker research. *PLoS One* 2018; 13: e0206478.
- 345 6. Seehusen DA, Reeves MM, Fomin DA. Cerebrospinal fluid analysis. *Am Fam Physician*346 2003; 68: 1103-8.
- Huang L, Ye H, Qu J, Liu Y, Zhong C, Tang G, et al. Analysis of cerebrospinal fluid
 protein concentrations of patients with cryptococcal meningitis treated with antifungal
 agents. *BMC Infect Dis* 2015; 15: 333.
- Biamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis. A study in 111
 cases. Ann Intern Med 1974; 80: 176-81.
- 9. Qu J, Jiang J, Lv X. The utility of cerebrospinal fluid white cell count during the
 prognostic assessment for cryptococcal meningitis patients: a retrospective study. *BMC Infect Dis* 2020; 20: 571.
- Bicanic T, Brouwer AE, Meintjes G, Rebe K, Limmathurotsakul D, Chierakul W, et al.
 Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with
 cryptococcal meningitis undergoing serial lumbar punctures. *AIDS* 2009; 23: 701-6.
- Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kambugu A, et al. Paucity
 of Initial Cerebrospinal Fluid Inflammation in Cryptococcal Meningitis Is Associated
 with Subsequent Immune Reconstitution Inflammatory Syndrome. *Journal of Infectious Diseases* 2010; 202: 962-70.
- Jarvis JN, Bicanic T, Loyse A, Namarika D, Jackson A, Nussbaum JC, et al.
 Determinants of mortality in a combined cohort of 501 patients with HIV-associated
 Cryptococcal meningitis: implications for improving outcomes. *Clin Infect Dis* 2014; 58:
 736-45.
- 13. Lawrence DS, Youssouf N, Molloy SF, Alanio A, Alufandika M, Boulware DR, et al.
 367 AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for

It is made available under a CC-BY 4.0 International license .

Kasibante CSF Protein in Cryptococcosis

368 369		Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. <i>Trials</i> 2018 ; 19: 649.
370 371 372	14.	Williams DA, Kiiza T, Kwizera R, Kiggundu R, Velamakanni S, Meya DB, et al. Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study. <i>Clin Infect Dis</i> 2015 ; 61: 464-7.
373 374 375	15.	Boulware DR, Rolfes MA, Rajasingham R, von Hohenberg M, Qin Z, Taseera K, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. <i>Emerg Infect Dis</i> 2014 ; 20: 45-53.
376 377 378	16.	Benjamini Y, Hochberg Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. <i>Journal of the Royal Statistical Society Series B-</i> <i>Statistical Methodology</i> 1995 ; 57: 289-300.
379 380 381	17.	Pullen MF, Hullsiek KH, Rhein J, Musubire AK, Tugume L, Nuwagira E, et al. Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials. <i>Clin Infect Dis</i> 2020 ; 71: e45-e9.
382 383 384 385	18.	Scriven JE, Graham LM, Schutz C, Scriba TJ, Wilkinson KA, Wilkinson RJ, et al. The CSF Immune Response in HIV-1-Associated Cryptococcal Meningitis: Macrophage Activation, Correlates of Disease Severity, and Effect of Antiretroviral Therapy. <i>J Acquir Immune Defic Syndr</i> 2017 ; 75: 299-307.
386 387 388 389	19.	Jarvis JN, Casazza JP, Stone HH, Meintjes G, Lawn SD, Levitz SM, et al. The phenotype of the Cryptococcus-specific CD4+ memory T-cell response is associated with disease severity and outcome in HIV-associated cryptococcal meningitis. <i>J Infect Dis</i> 2013 ; 207: 1817-28.
390 391 392	20.	Jarvis JN, Meintjes G, Bicanic T, Buffa V, Hogan L, Mo S, et al. Cerebrospinal fluid cytokine profiles predict risk of early mortality and immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis. <i>PLoS Pathog</i> 2015 ; 11: e1004754.
393 394 395	21.	Neal LM, Xing E, Xu J, Kolbe JL, Osterholzer JJ, Segal BM, et al. CD4(+) T Cells Orchestrate Lethal Immune Pathology despite Fungal Clearance during Cryptococcus neoformans Meningoencephalitis. <i>mBio</i> 2017 ; 8: pii: e01415-17.
396 397 398	22.	Geiser T, Dewald B, Ehrengruber MU, Clark-Lewis I, Baggiolini M. The interleukin-8- related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes. <i>J Biol Chem</i> 1993 ; 268: 15419-24.
399	23.	Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol 2008; 20: 288-94.
400 401	24.	Zenobia C, Hajishengallis G. Basic biology and role of interleukin-17 in immunity and inflammation. <i>Periodontol 2000</i> 2015 ; 69: 142-59.
402 403	25.	Aziz N, Detels R, Chang LC, Butch AW. Macrophage Inflammatory Protein-3 Alpha (MIP-3alpha)/CCL20 in HIV-1-Infected Individuals. <i>J AIDS Clin Res</i> 2016 ; 7.
404 405 406	26.	Che YM, Zhang Y, Li M, Li XP, Zhang LL. In vitro and in vivo effect of PD-1/PD-L1 blockade on microglia/macrophage activation and T cell subset balance in cryptococcal meningitis. <i>J Cell Biochem</i> 2018 ; 119: 3044-57.

It is made available under a CC-BY 4.0 International license .

Kasibante CSF Protein in Cryptococcosis

407 408 409	27.	Malyak M, Smith MF, Jr., Abel AA, Hance KR, Arend WP. The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. <i>J Immunol</i> 1998 ; 161: 2004-10.
410 411	28.	Ross SH, Cantrell DA. Signaling and Function of Interleukin-2 in T Lymphocytes. <i>Annu Rev Immunol</i> 2018 ; 36: 411-33.
412 413 414	29.	Ma LL, Wang CLC, Neely GG, Epelman S, Krensky AM, Mody CH. NK cells use perforin rather than granulysin for anticryptococcal activity. <i>Journal of Immunology</i> 2004 ; 173: 3357-65.
415 416 417	30.	Zheng CF, Ma LL, Jones GJ, Gill MJ, Krensky AM, Kubes P, Mody CH. Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. <i>Blood</i> 2007 ; 109: 2049-57.
418 419	31.	Rohatgi S, Pirofski LA. Host immunity to Cryptococcus neoformans. <i>Future Microbiol</i> 2015 ; 10: 565-81.
420 421 422	32.	Tugume L, Rhein J, Hullsiek KH, Mpoza E, Kiggundu R, Ssebambulidde K, et al. HIV- Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts. <i>Journal of Infectious Diseases</i> 2019 ; 219: 877-83.
423 424 425	33.	Lofgren S, Hullsiek KH, Morawski BM, Nabeta HW, Kiggundu R, Taseera K, et al. Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis. <i>Journal of Infectious Diseases</i> 2017 ; 215: 693-7.
426 427	34.	Pirofski LA, Casadevall A. The damage-response framework of microbial pathogenesis and infectious diseases. <i>Adv Exp Med Biol</i> 2008 ; 635: 135-46.
428 429 430 431	35.	Scriven JE, Rhein J, Hullsiek KH, von Hohenberg M, Linder G, Rolfes MA, et al. Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial. <i>J Infect Dis</i> 2015 ; 212: 769-78.
432 433 434 435	36.	Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. <i>Cancer Discov</i> 2018 ; 8: 958-71.



